Journal
EXPERIMENTAL AND THERAPEUTIC MEDICINE
Volume 22, Issue 3, Pages -Publisher
SPANDIDOS PUBL LTD
DOI: 10.3892/etm.2021.10392
Keywords
pregnancy; breastfeeding; hyperthyroidism; propylthiouracil; methimazole; thyroid dysfunction in pregnancy; gestational thyrotoxicosis
Categories
Ask authors/readers for more resources
Thyroid dysfunction is more common in women and can have significant impacts on fetal development and pregnancy outcomes. Untreated or poorly treated hyperthyroidism can lead to higher rates of pregnancy loss. Prompt treatment during pregnancy is crucial to ensure the health of the fetus.
Thyroid dysfunction is a significant public health issue, affecting 5-10 more women compared to men. The estimated incidence is up to 12% and only for women the treatment rises up to 4.3 billion dollars annually. Thyroid pathology can have a major impact on female fertility and it can only be detected when preconception tests are performed. Untreated or poorly treated hyperthyroidism in a mother can affect the fetal development and pregnancy outcome. Between 0.1 and 0.4% of the pregnancies are affected by clinical hyperthyroidism. Thyroid dysfunction is associated with higher rates of pregnancy loss. Hyperthyroidism can complicate fetal health problems intrauterinely and in the neonatal period. The TSH receptor is stimulated by TSH and HCG which has a similar structure. This can lead to gestational thyrotoxicosis. Hyperthyroidism can be treated with propylthiouracil or methimazole and in selected cases, surgical treatment or radioactive iodine can be chosen. In pregnancy, the most used treatment is represented by propylthiouracil which can be used from the first trimester. The aim of this review is to assess the current data regarding the impact of thyroid dysfunction on pregnancy and to synthesize the treatment options during pregnancy and lactation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available